You can buy or sell Synlogic and other stocks, options, ETFs, and crypto commission-free!
Synlogic, Inc. Common Stock, also called Synlogic, is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. Read More It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMay 22
Synlogic teams up with Roche in potential combo therapy for solid tumors
Synlogic (NASDAQ:SYBX) will collaborate with Roche (OTCQX:RHHBY) on clinical studies evaluating the combination of SYNB1891, a STING agonist, and Tecentriq (atezolizumab) in patients with advanced solid tumors.
Seeking AlphaMay 12
Synlogic, Inc. CEO Aoife Brennan on Q1 2019 Results - Earnings Call Transcript
Synlogic, Inc. (NASDAQ:SYBX) Q1 2019 Results Earnings Conference Call May 9, 2019 5:00 PM ET Company Participants Elizabeth Wolffe - Head, IR and Corporate Communications Aoife Brennan - President, CEO, and CMO Scott Plevy - CSO Todd Shegog - CFO Conference Call Participants Mark Breidenbach - Oppenheimer & Co Inc. Joseph Schwartz - SVB Leerink Samantha Semenkow - Citigroup Ted Tenthoff - Piper Jaffray & Co. Edward Marks - H.C. Wainwright & Co. Chris Howerton - Jefferies Julian Harrison - BTIG ...
Yahoo FinanceMay 9
Synlogic Reports First Quarter 2019 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- – Company will host a conference call and webcast at 5:00 pm ET today – Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial results for the first quarter ended March 31, 2019. “We made significant progress on our 2019 goals in the first quarter of the year providing a strong foundation for the continued development of our Synthetic Biotic™ platform and...
Expected Aug 7, After Hours